March 2018 Pharmaceutical Schedule Dispatch
This document is provided to pharmacists as an early notification of the changes to be announced in the March 2018 Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings
- Calcium folinate (Calcium Folinate Sandoz) inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist (p’code 2539195)
- Calcium folinate (Calcium Folinate Sandoz) inj 10 mg per ml, 10 ml (p’code 2539209) and 35 ml (p’code 2539217) vials – PCT only – Specialist
- Dacarbazine (APP Pharmaceuticals) inj 200 mg vial – PCT only – Specialist, S29 (p’code 2539446)
- Influenza vaccine (Influvac Tetra) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – only on a prescription, no patient co-payment payable, access restriction applies (p’code 2538466)
- Influenza vaccine (Fluarix Tetra) inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) – only on a prescription, no patient co-payment payable, access restriction applies (p’code 2539586)
- Oral feed (powder) (Fortisip) powder (vanilla) 857 g OP – Special Authority – Hospital pharmacy [HP3] (p’code 2526638)

Changes to restrictions, chemical names and presentations
- Bisoprolol fumarate (Bosvate) tab 2.5 mg, 5 mg and 10 mg – addition of STAT dispensing
- Bosentan (Mylan-Bosentan and Bosentan-Mylan) tab 62.5 mg and 125 mg – amended Special Authority criteria
- Emtricitabine with tenofovir disoproxil fumarate (Truvada) tab 200 mg with tenofovir disoproxil fumarate 300 mg – Subsidy by endorsement added and amended Special Authority criteria
- Influenza vaccine (Influvac) inj 45 mcg in 0.5 ml syringe – Sole Supply revoked and delisting
- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Moloxole and Lax-Sachets) Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – Special Authority and maximum of 90 sach per prescription removed
- Mask for spacer device (e-chamber Mask) small – PSO quantity increased to 50 dev
- Peak flow meter low range (Mini-Wright AFS Low Range) and normal range (Mini-Wright Standard) – PSO quantity increased to 25 dev
Changes to restrictions, chemical names and presentations (continued)

- Prednisolone sodium phosphate (Minims Prednisolone) eye drops 0.5%, single dose (preservative free) – amended Special Authority criteria
- Simvastatin (Simvastatin Mylan and Arrow-Simva) tab 10 mg, 20 mg, 40 mg and 80 mg – addition of STAT dispensing
- Spacer device 220 ml (single patient) (e-chamber Turbo), 510 ml (single patient) (e-chamber La Grande), and 800 ml (Volumatic) – PSO quantity increased to 50 dev

Increased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colestipol hydrochloride</td>
<td>Gran for oral liq 5 g</td>
<td>Colestid</td>
</tr>
<tr>
<td>Cytarabine</td>
<td>Inj 100 mg per ml, 20 ml vial</td>
<td>Pfizer, Baxter</td>
</tr>
<tr>
<td>Dactinomycin [actinomycin D]</td>
<td>Inj 0.5 mg vial</td>
<td>Cosmegen, Baxter</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Tab 10 mg and 20 mg</td>
<td>Genox</td>
</tr>
</tbody>
</table>

Decreased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
<th>Partially subsidised brands*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe</td>
<td>Tab 10 mg</td>
<td>Ezetimibe Sandoz*</td>
<td>Ezemibe</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>Cap 10 mg, 20 mg and 40 mg</td>
<td>Omeprazole actavis*</td>
<td>Omezol Relief</td>
</tr>
<tr>
<td>Pravastatin</td>
<td>Tab 20 mg and 40 mg</td>
<td>Apo-Pravastatin*</td>
<td>Chlorvastin</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>Tab 20 mg, Tab 40 mg, Tab 80 mg</td>
<td>Simvastatin Mylan*</td>
<td>Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg</td>
</tr>
</tbody>
</table>

* no subsidy changes for these brands for 1 March 2018.

Changes to the Pharmaceutical Schedule Rules – consultation

PHARMAC has begun consultation on changes to the Pharmaceutical Schedule Rules, to make them easier to find, use and apply.

PHARMAC is proposing to tidy up the rules by bringing them together in one place and removing redundant text. Practical resources will be developed to help explain the rules.

The proposed changes to the Schedules Rules should make it easier for health professionals to help their patients, but PHARMAC wants to hear from you to make sure we get this right.

Consultation on the proposed changes to the Pharmaceutical Schedule rules is on our website (https://www.pharmac.govt.nz/news/consultation-2018-02-15-schedule-rules-changes/) and is open until Thursday 29 March 2018. We encourage you to respond to it.